The invention herein is directed to a selective Aß oligomer immunoassay capable of reliably and sensitively detecting Aß oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aß oligomer antibodies, 19.3 and 82E1, to detect and quantify Aß oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aß oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.
METHOD FOR DETECTION OF AMYLOID BETA OLIGOMERS IN A FLUID SAMPLE AND USES THEREOF